Generic Zerviate Availability
Last updated on Sep 11, 2024.
Zerviate is a brand name of cetirizine ophthalmic, approved by the FDA in the following formulation(s):
ZERVIATE (cetirizine hydrochloride - solution/drops;ophthalmic)
-
Manufacturer: HARROW EYE
Approval date: May 30, 2017
Strength(s): EQ 0.24% BASE [RLD]
Has a generic version of Zerviate been approved?
No. There is currently no therapeutically equivalent version of Zerviate available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zerviate. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Ophthalmic formulations of cetirizine and methods of use
Patent 8,829,005
Issued: September 9, 2014
Inventor(s): Abelson Mark Barry & Chapin Matthew J. & Gomes Paul & Minno George & Nice Jackie
Assignee(s): Aciex Therapeutics, Inc.The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Patent expiration dates:
- March 15, 2030✓
- March 15, 2030
-
Ophthalmic formulations of cetirizine and methods of use
Patent 8829005*PED
Issued: September 9, 2014
Inventor(s): Abelson Mark Barry & Chapin Matthew J. & Gomes Paul & Minno George & Nice Jackie
Assignee(s): Aciex Therapeutics, Inc.The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Patent expiration dates:
- September 15, 2030✓
- September 15, 2030
-
Ophthalmic formulations of cetirizine and methods of use
Patent 9,254,286
Issued: February 9, 2016
Inventor(s): Abelson Mark B. & Chapin Matthew J. & Gomes Paul & Minno George & Nice Jackie
Assignee(s): Aciex Therapeutics, Inc.The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Patent expiration dates:
- July 9, 2032✓
- July 9, 2032
-
Ophthalmic formulations of cetirizine and methods of use
Patent 9254286*PED
Issued: February 9, 2016
Inventor(s): Abelson Mark B. & Chapin Matthew J. & Gomes Paul & Minno George & Nice Jackie
Assignee(s): Aciex Therapeutics, Inc.The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Patent expiration dates:
- January 9, 2033✓
- January 9, 2033
-
Ophthalmic formulations of cetirizine and methods of use
Patent 9,750,684
Issued: September 5, 2017
Inventor(s): Abelson Mark Barry & Chapin Matthew J. & Gomes Paul & Minno George & Nice Jackie
Assignee(s): Nicox Ophthalmics, Inc.The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Patent expiration dates:
- March 15, 2030✓
- March 15, 2030
-
Ophthalmic formulations of cetirizine and methods of use
Patent 9,993,471
Issued: June 12, 2018
Inventor(s): Abelson Mark Barry & Chapin Matthew J. & Gomes Paul & Minno George & Nice Jackie
Assignee(s): NICOX OPHTHALMICS, INC.The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Patent expiration dates:
- March 15, 2030✓
- March 15, 2030
More about Zerviate (cetirizine ophthalmic)
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: ophthalmic antihistamines and decongestants
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.